Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926117 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT03926117 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 264 participants.
The verdict
NCT03926117, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 mg and 30 mg subcutaneous monthly compared to placebo for six months.
Interventions
- BIOLOGICAL Ziltivekimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2020-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926117
The ClinicalTrials.gov registry entry for NCT03926117 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziltivekimab is the first listed.
NCT03926117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926117 about?
NCT03926117 is a clinical study titled "Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition". Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be...
What is the current status of trial NCT03926117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2019-06-03. Estimated completion is 2020-06-26.
What interventions are being tested in trial NCT03926117?
The interventions under investigation include: Ziltivekimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03926117?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.